Date post: | 18-Nov-2014 |
Category: |
Education |
Upload: | dr-awadhesh-sharmadr-ram-manoher-lohia-hospital-new-delhi |
View: | 991 times |
Download: | 0 times |
Journal Club
Dr Awadhesh Kumar Sharma
Intracoronary Compared with Intravenous Bolus Abciximab Application
During Primary Percutaneous Coronary Intervention
Cardiac Magnetic Resonance Substudy of the AIDA STEMI trial
Holger Thiele, MD; Jochen Wöhrle, MDHenning Suenkel, BSc; Josephine Meissner, MD; Sebastian Kerber, MD;
Bernward Lauer, MD; Matthias Pauschinger, MD; Ralf Birkemeyer, MD; Christoph Axthelm, MD; Rainer Zimmermann, MD; Petra Neuhaus, PhD; Oana Brosteanu, PhD; Steffen Desch, MD;
Matthias Gutberlet, MD; Gerhard Schuler, MD; Ingo Eitel, MDon behalf of the AIDA STEMI Investigators
Off-label use of IC abciximab
Disclosures
Funding:Unrestricted grant by Lilly, GermanyUniversity of Leipzig – Heart CenterUniversity of Leipzig, Clinical Trial Centre Leipzig: supported by the Federal Ministry of Education and Research (BMBF) FKZ 01KN1102
Potential Conflict of Interest: Research Funding:
Terumo, Lilly. Maquet Cardiovascular, Teleflex MedicalConsulting:Maquet Cardiovascular, AvidalSpeaker Honoraria:Lilly, Astra Zeneca, Daiichi Sankyo, Boehringer Ingelheim, Maquet Cardiovascular, Medicines Company
INTRODUCTION Randomized studies have consistently shown
that treatment with an adjunctive glycoprotein IIb/IIIa inhibitor improves coronary microcirculation and clinical outcome in high-risk ST-segment elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI).
Intracoronary abciximab bolus administration results in higher local concentrations and increased levels of platelet glycoprotein IIb/IIIa receptor occupancy compared with standard intravenous application
Abciximab IC versus IV
Navarese et al. Platelets 2011;1-8
Background
CICERO 2010CRYSTAL AMI 2010Dominguez-Rodriguez 2009EASY-MI 2010Iversen 2011Thiele 2008
500022
27125255318577
710093
26323255217077
33.7%7.4%
44.8%14.1%
0.690.29 (0.01;7.59)Not estimableNot estimable0.20 (0.04;0.92)0.66 (0.11;4.05)
Study or SubgroupIntracoronary abciximabIntravenous abciximab Odds ratio
Events Total Events Total Weight M-H, Fixed 95%
Total (95%)
Total events
636 610 100.0% 0.43 (0.20;0.94)9 20
Heterogeneity: Chi2 =1.88, df=3 (P=0.60);I2=0%Test for overall effect: Z=2.11 (P=0.03)
30-day Mortality
M-H, Fixed 95%Odds ratio
Favors IC Favors IV0.01 0.1 1 10 100
Favors IC Favors IV
CICERO 2010EASY-MI 2010Iversen 2011Thiele 2008
30-day Myocardial Infarction
3050
2715318577
4082
2635217077
27.5%
55.5%17.0%
Study or SubgroupIntracoronary abciximab Intravenous abciximab Odds ratio
Events Total Events Total Weight M-H, Fixed 95%
Total (95%)
Total events636
562 100.0% 0.54 (0.23;1.28)
8 14
Heterogeneity: Chi2 =0.58, df=2 (P=0.75);I2=0%
Test for overall effect: Z=1.39 (P=0.17)
M-H, Fixed 95%Odds ratio
0.01 0.1 1 10 100
0.72 (0.16;3.27)Not estimable0.56 (0.18;1.75)0.19 (0.01;4.13)
586
CICERO 2010EASY-MI 2010Iversen 2011Thiele 2008
30-day Target Vessel Revascularization
9070
2715318577
100162
2635217077
27.5%
55.5%17.0%
Study or SubgroupIntracoronary abciximab Intravenous abciximab Odds ratio
Events Total Events Total Weight M-H, Fixed 95%
Total (95%)Total events 636
562 100.0% 0.53 (0.29;0.99)
16 28Heterogeneity: Chi2 =2.58, df=2 (P=0.36);I2=2%
Test for overall effect: Z=2.00 (P=0.05)
M-H, Fixed 95%Odds ratio
Favors IC Favors IV0.01 0.1 1 10 100
0.87 (0.35;2.17)Not estimable0.38 (0.15;0.94)0.19 (0.01;4.13)
586
The large, randomized AIDA STEMI (Abciximab Intracoronary versus intravenously Drug Application in STEMI) multicenter trial, intracoronary abciximab application did not result in a difference in major adverse cardiac events (MACE) compared with the standard intravenous route , but the rate of new congestive heart failure was significantly lower and there was an observed benefit in the female subgroup.
The Abciximab Intracoronary versus intravenously Drug Application in ST-Elevation Myocardial Infarction
(AIDA STEMI) trial
Methodology• Primary Study Endpoint:
Composite of all-cause death, reinfarction, new congestive heart failure at 90 days after randomization
• Secondary Study Endpoints: - Time to occurrence of combined clinical endpoint- TIMI-flow post PCI- ST-segment resolution- Infarct size by AUC of CK-release
Thiele et al. Circulation 2008;118:49-57Thiele et al. Am Heart J 2010;159:547-554
Methods
1032 patients randomized to IC abciximab
1002 patients PCI started
995 patients abciximab bolus given; PCI
completed
935 patients with 90 day follow-up
Study Design, Flow, and Compliance2065 patients with suspected STEMI
- STEMI with symptoms <12 h - Planned primary PCI
- no contraindication for abciximab
8 technical PCI-problems7 exclusion criteria detected
UFH 50-70 IU/kgAspirin 500 mg, Clopidogrel 600 mg/Prasugrel 60 mg
Abciximab bolus 0.25 mg/kg plus 12 h infusion 0.125 µg/kg/min
1033 patients randomized to IV abciximab
1001 patients PCI started
993 patients abciximab bolus given; PCI
completed
932 patients with 90 day follow-up
64 withdrawal informed consent32 lost to follow-up25 incomplete information
62 patients not PCI eligible:- 46 STEMI not
confirmed- 13 emergency
CABG- 3 exclusion
criteria
Primary Outcome and Components
IC IV OR 95% CI P
Death/Reinfarction/new CHF
n/total n (%) 65/935 (7.0) 71/932 (7.6) 0.91 0.91-1.28 0.58
Death
Overalln/total n (%) 42/935 (4.5) 34/932 (3.6) 1.24 0.78-1.97 0.36
Cardiac 35 33
Non-cardiac 7 1
Reinfarction
n/total n (%) 17/935 (1.8) 17/932 (1.8) 1.0 0.51-1.96 0.99
New CHF
n/total n (%) 22/935 (2.4) 38/935 (4.1) 0.57 0.33-0.97 0.04
Results
Summary + Conclusions• This randomized, multi-center, large-scale trial
involving more than 2000 STEMI patients undergoing primary PCI showed that IC abciximab bolus administration is safe.
• The IC bolus administration of abciximab does not add a benefit in comparison to the standard IV bolus with respect to the combined primary study endpoint consisting of death, reinfarction, or new congestive heart failure within 90 days.
• The IC route might be related to reduced rates of new congestive heart failure.
Combined Clinical Endpoint
Time from randomization [days]
Cu
mu
lati
ve e
ven
t fr
ee s
urv
ival
fro
m
dea
th, r
ein
farc
tio
n a
nd
co
ng
esti
ve h
eart
fai
lure
[%
]
p=0.54
Intracoronary Abciximab
Intravenous Abciximab
Thiele et al. Lancet 2012;379:923-31
Background
Congestive Heart Failure
p=0.03
Intracoronary Abciximab
Intravenous Abciximab
Time from randomization [days]
Cu
mu
lati
ve e
ven
t fr
ee s
urv
ival
of
con
ges
tive
hea
rt f
ailu
re [
%]
Thiele et al. Lancet 2012;379:923-31
Background
AIDA-STEMI CMR Substudy
• CMR enables investigation of mechanistic and pathophysiological effects of intracoronary + intravenous abciximab application on myocardial damage and reperfusion injury.
• To determine potential benefits of intracoronary abciximab application on infarct size, myocardial salvage, microvascular obstruction and ventricular function to further evaluate the benefit with respect to congestive heart failure.
Thiele et al. Am Heart J 2010;159:547-554
Study Organization and Study Sites
DSMB:Uwe ZeymerHans-Richard ArntzChristoph BodeKarl WegscheiderSteering Committee:Holger ThieleJochen WöhrleOana BrosteanuGerhard Schuler
CRO:Clinical Trial Center Leipzig
Investigator Initiated Trial
Methods
22 study sites in Germany8 CMR study sitesCMR core laboratory:Ingo Eitel (Coordinator)Josephine MeissnerHenning SünkelHolger Thiele
RESULTS
Patient characteristics
Patients in the 2 groups had similar baseline characteristics except for hypertension and previous bypass surgery.
All other prescribed drugs and study procedures were similar for both groups
CMR RESULTS
The median time between the index eventand CMR was 3 days (IQR: 2 to 4 days) for both groups
Clinical outcome and relationship of CMR markers and
clinical outcome
At 12-month follow-up, there were 13 deaths (3.3%) in the intracoronary and 8 (2.0%) in the intravenous abciximab groups (hazard ratio: 1.69; 95% confidence interval: 0.69 to 4.11; p= 0.25).
There were also no significant differences in the occurrence of nonfatal re-infarctions (p = 0.54) and congestive heart failure (p = 0.11).
Consequently, MACE at 12-month follow-up were similar (intracoronary 24 [6.2%] vs. intravenous 29 [7.3%] events; hazard ratio: 0.84; 95% confidence interval: 0.48 to 1.46; p= 0.53)
Patients in whom MACE occurred had significantly larger infarcts, less myocardial salvage, and more pronounced LV dysfunction
Intramyocardial hemorrhage and MO as markers of severe reperfusion injury were more frequent in patients with MACE without reaching statistical significance.
Summary + Conclusions
• This largest multicenter CMR study in STEMI patients to date demonstrates that IC as compared to IV abciximab did not result in a difference in myocardial damage and/or reperfusion injury.
• The results of the AIDA STEMI CMR substudy therefore confirm the lack of difference in the combined endpoint of death, reinfarction or congestive heart failure of the AIDA STEMI trial.
THANKS